Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 8;16(5):682-684.
doi: 10.2215/CJN.03270321. Epub 2021 Apr 27.

Novel Therapeutic Options for Cardiovascular Disease with CKD

Carmine Zoccali  1 , Francesca Mallamaci  2
Affiliations
Editorial

Novel Therapeutic Options for Cardiovascular Disease with CKD

Carmine Zoccali et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: apabetalone; cardiovascular disease; chronic kidney disease; epigenetic modifiers; heart failure; mortality risk.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The figure shows the DNA rolled around histone proteins. These proteins exhibit “tails,” which are the site for post-translational modifications. Enzymes (writers) place chemical signatures (methylation, phosphorylation, acetylation) on histone tails, and other proteins (readers) bind to histone signatures in order to facilitate the assembly of transcriptional machinery. These signatures activate highly integrated transcriptional programs, dictating adaptive responses. Signatures by writers can be deleted by other enzymes (erasers). Bromodomain (BRD) and extra terminal containing (BET) proteins are epigenetic readers, and apabetalone is a BET inhibitor.
See this image and copyright information in PMC

Comment on

References

    1. Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Garofalo C, Chiodini P, Ceriello A, Esposito K: Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney. Cardiovasc Diabetol 19: 35, 2020. - PMC - PubMed
    1. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet 385: 2047–2056, 2015. - PubMed
    1. Pradhan AD, Aday AW, Rose LM, Ridker PM: Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation 138: 141–149, 2018. - PMC - PubMed
    1. Mirbahai L, Chipman JK: Epigenetic memory of environmental organisms: A reflection of lifetime stressor exposures. Mutat Res Genet Toxicol Environ Mutagen 764–765: 10–17, 2014. - PubMed
    1. Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, Wu J, McLure KG, Hansen HC, Wagner GS, Young PR, Srivastava RAK, Wong NCW, Johansson J: A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis 236: 91–100, 2014. - PubMed

MeSH terms